share_log

Allogene Therapeutics Analyst Ratings

Allogene Therapeutics Analyst Ratings

Allogene Therapeutic
Benzinga ·  2023/09/25 09:33
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
09/25/2023 146.58% JP Morgan $11 → $9 Maintains Overweight
08/07/2023 530.14% HC Wainwright & Co. → $23 Reiterates Buy → Buy
08/03/2023 667.12% Oppenheimer → $28 Reiterates Outperform → Outperform
08/03/2023 310.96% EF Hutton → $15 Reiterates Buy → Buy
07/12/2023 393.15% Truist Securities $20 → $18 Maintains Buy
06/26/2023 667.12% Oppenheimer → $28 Assumes → Outperform
06/20/2023 530.14% HC Wainwright & Co. → $23 Reiterates Buy → Buy
06/16/2023 858.9% Canaccord Genuity → $35 Reiterates Buy → Buy
06/05/2023 310.96% JMP Securities → $15 Reiterates → Market Outperform
06/05/2023 310.96% EF Hutton → $15 Reiterates Buy → Buy
05/26/2023 310.96% EF Hutton → $15 Reiterates Buy → Buy
05/05/2023 310.96% JMP Securities $19 → $15 Maintains Outperform
05/05/2023 530.14% HC Wainwright & Co. → $23 Reiterates → Buy
05/04/2023 105.48% Stifel $8 → $7.5 Maintains Hold
05/04/2023 310.96% RBC Capital → $15 Reiterates → Outperform
04/20/2023 530.14% HC Wainwright & Co. → $23 Reiterates → Buy
04/18/2023 420.55% JMP Securities → $19 Reiterates → Market Outperform
04/17/2023 310.96% EF Hutton → $15 Maintains Buy
04/04/2023 530.14% HC Wainwright & Co. $29 → $23 Maintains Buy
03/21/2023 64.38% Bernstein → $6 Initiates Coverage On → Market Perform
03/02/2023 749.32% Goldman Sachs $35 → $31 Maintains Buy
03/02/2023 420.55% JMP Securities $23 → $19 Maintains Market Perform
03/01/2023 502.74% RBC Capital $32 → $22 Maintains Outperform
03/01/2023 667.12% Oppenheimer $32 → $28 Maintains Outperform
03/01/2023 749.32% Goldman Sachs $35 → $31 Maintains Buy
03/01/2023 310.96% EF Hutton → $15 Reiterates → Buy
01/24/2023 201.37% JP Morgan $20 → $11 Upgrades Neutral → Overweight
01/06/2023 228.77% Baird → $12 Upgrades Neutral → Outperform
01/05/2023 310.96% EF Hutton → $15 Initiates Coverage On → Buy
12/12/2022 146.58% B of A Securities → $9 Downgrades Buy → Underperform
11/21/2022 694.52% HC Wainwright & Co. $43 → $29 Maintains Buy
09/22/2022 393.15% B. Riley Securities $21 → $18 Maintains Buy
08/10/2022 858.9% Oppenheimer $40 → $35 Maintains Outperform
08/10/2022 776.71% RBC Capital $35 → $32 Maintains Outperform
08/10/2022 — Raymond James Downgrades Outperform → Market Perform
07/15/2022 776.71% Goldman Sachs $9 → $32 Upgrades Neutral → Buy
06/03/2022 201.37% Baird → $11 Initiates Coverage On → Neutral
05/24/2022 146.58% Goldman Sachs $12 → $9 Maintains Neutral
05/05/2022 256.16% Raymond James $36 → $13 Maintains Outperform
03/07/2022 228.77% Goldman Sachs $20 → $12 Maintains Neutral
12/14/2021 858.9% RBC Capital $45 → $35 Maintains Outperform
10/12/2021 639.73% JMP Securities $53 → $27 Maintains Market Outperform
10/08/2021 — Stifel Downgrades Buy → Hold
10/08/2021 1132.88% RBC Capital $55 → $45 Maintains Outperform
10/08/2021 447.95% Goldman Sachs $71 → $20 Downgrades Buy → Neutral
09/24/2021 886.3% Raymond James → $36 Upgrades Market Perform → Outperform
09/23/2021 886.3% Raymond James → $36 Upgrades Market Perform → Outperform
05/20/2021 1023.29% Truist Securities $34 → $41 Upgrades Hold → Buy
05/14/2021 1324.66% B. Riley Securities → $52 Initiates Coverage On → Buy
03/01/2021 1078.08% HC Wainwright & Co. $40 → $43 Maintains Buy
01/26/2021 1078.08% Stifel $33 → $43 Upgrades Hold → Buy
12/10/2020 995.89% HC Wainwright & Co. → $40 Assumes → Buy
10/23/2020 1406.85% RBC Capital → $55 Initiates Coverage On → Outperform
06/12/2020 1242.47% HC Wainwright & Co. $55 → $49 Maintains Buy
06/01/2020 1406.85% Oppenheimer $50 → $55 Maintains Outperform
06/01/2020 — Raymond James Downgrades Outperform → Market Perform
05/19/2020 1543.84% Roth Capital → $60 Upgrades Neutral → Buy
05/15/2020 — Guggenheim Upgrades Neutral → Buy
05/14/2020 1105.48% Canaccord Genuity $36 → $44 Maintains Buy
05/14/2020 1269.86% Oppenheimer $44 → $50 Maintains Outperform
05/14/2020 1050.68% HC Wainwright & Co. $35 → $42 Reiterates → Buy
05/14/2020 776.71% SunTrust Robinson Humphrey $29 → $32 Downgrades Buy → Hold
04/13/2020 694.52% SunTrust Robinson Humphrey → $29 Initiates Coverage On → Buy
02/24/2020 639.73% Berenberg → $27 Initiates Coverage On → Hold
12/18/2019 913.7% JMP Securities → $37 Initiates Coverage On → Market Outperform
11/04/2019 886.3% Canaccord Genuity → $36 Initiates Coverage On → Buy
08/09/2019 913.7% BTIG → $37 Initiates Coverage On → Buy
06/05/2019 612.33% Roth Capital → $26 Initiates Coverage On → Neutral
05/31/2019 — Guggenheim Initiates Coverage On → Neutral
05/23/2019 639.73% Stifel → $27 Initiates Coverage On → Hold
05/03/2019 1132.88% Oppenheimer → $45 Initiates Coverage On → Outperform
03/29/2019 1269.86% Piper Sandler → $50 Initiates Coverage On → Overweight
03/15/2019 995.89% Raymond James → $40 Initiates Coverage On → Outperform
03/14/2019 — William Blair Initiates Coverage On → Outperform
11/05/2018 — Cowen & Co. Initiates Coverage On → Outperform
11/05/2018 694.52% JP Morgan → $29 Initiates Coverage On → Neutral
11/05/2018 749.32% Jefferies → $31 Initiates Coverage On → Buy
11/05/2018 1023.29% Goldman Sachs → $41 Initiates Coverage On → Buy
日期 上行/下行 分析公司 目标价格变化 评级变化 上一次/当前评级
09/25/2023 146.58% 摩根大通 $11→$9 维护 超重
08/07/2023 530.14% HC Wainwright公司 →$23 重申 购买→购买
08/03/2023 667.12% 奥本海默 →$28 重申 跑赢→跑赢大盘
08/03/2023 310.96% EF Hutton →$15 重申 购买→购买
07/12/2023 393.15% Truist证券 $20→$18 维护 买
2023/06/26 667.12% 奥本海默 →$28 假设 →跑赢大盘
06/20/2023 530.14% HC Wainwright公司 →$23 重申 购买→购买
06/16/2023 858.9% 卡纳科特·格纳奇 →$35 重申 购买→购买
06/05/2023 310.96% JMP证券 →$15 重申 →市场跑赢大盘
06/05/2023 310.96% EF Hutton →$15 重申 购买→购买
2023年05月26日 310.96% EF Hutton →$15 重申 购买→购买
05/05/2023 310.96% JMP证券 $19→$15 维护 跑赢大盘
05/05/2023 530.14% HC Wainwright公司 →$23 重申 →购买
05/04/2023 105.48% Stifel $8→$7.5 维护 保持
05/04/2023 310.96% 加拿大皇家银行资本 →$15 重申 →跑赢大盘
04/20/2023 530.14% HC Wainwright公司 →$23 重申 →购买
04/18/2023 420.55% JMP证券 →$19 重申 →市场跑赢大盘
04/17/2023 310.96% EF Hutton →$15 维护 买
04/04/2023 530.14% HC Wainwright公司 $29→$23 维护 买
03/21/2023 64.38% 伯恩斯坦 →$6 开始承保 →市场表现
03/02/2023 749.32% 高盛 $35→$31 维护 买
03/02/2023 420.55% JMP证券 $23→$19 维护 市场表现
03/01/2023 502.74% 加拿大皇家银行资本 $32→$22 维护 跑赢大盘
03/01/2023 667.12% 奥本海默 $32→$28 维护 跑赢大盘
03/01/2023 749.32% 高盛 $35→$31 维护 买
03/01/2023 310.96% EF Hutton →$15 重申 →购买
01/24/2023 201.37% 摩根大通 $20→$11 升级 中性→超重
01/06/2023 228.77% 贝尔德 →$12 升级 中性→表现优异
01/05/2023 310.96% EF Hutton →$15 开始承保 →购买
2022年12月12日 146.58% B of A证券 →$9 评级下调 购买表现不佳的→
2022年11月21日 694.52% HC Wainwright公司 $43→$29 维护 买
09/22/2022 393.15% B.莱利证券 $21→$18 维护 买
2022年08月10日 858.9% 奥本海默 $40→$35 维护 跑赢大盘
2022年08月10日 776.71% 加拿大皇家银行资本 $35→$32 维护 跑赢大盘
2022年08月10日 - 雷蒙德·詹姆斯 评级下调 跑赢→市场表现
07/15/2022 776.71% 高盛 $9→$32 升级 中性→购买
06/03/2022 201.37% 贝尔德 →$11 开始承保 →中性
2022年05月24日 146.58% 高盛 $12→$9 维护 中性
05/05/2022 256.16% 雷蒙德·詹姆斯 $36→$13 维护 跑赢大盘
03/07/2022 228.77% 高盛 $20→$12 维护 中性
2021年12月14日 858.9% 加拿大皇家银行资本 $45→$35 维护 跑赢大盘
10/12/2021 639.73% JMP证券 $53→$27 维护 市场表现强于大盘
10/08/2021 - Stifel 评级下调 购买→Hold
10/08/2021 1132.88% 加拿大皇家银行资本 $55→$45 维护 跑赢大盘
10/08/2021 447.95% 高盛 $71→$20 评级下调 购买→中性
09/24/2021 886.3% 雷蒙德·詹姆斯 →$36 升级 市场表现优于→
09/23/2021 886.3% 雷蒙德·詹姆斯 →$36 升级 市场表现优于→
05/20/2021 1023.29% Truist证券 $34→$41 升级 持有→购买
2021/05/14 1324.66% B.莱利证券 →$52 开始承保 →购买
03/01/2021 1078.08% HC Wainwright公司 $40→$43 维护 买
2021/01/26 1078.08% Stifel $33→$43 升级 持有→购买
12/10/2020 995.89% HC Wainwright公司 →$40 假设 →购买
10/23/2020 1406.85% 加拿大皇家银行资本 →$55 开始承保 →跑赢大盘
2020/06/12 1242.47% HC Wainwright公司 $55→$49 维护 买
06/01/2020 1406.85% 奥本海默 $50→$55 维护 跑赢大盘
06/01/2020 - 雷蒙德·詹姆斯 评级下调 跑赢→市场表现
2020/05/19 1543.84% 罗斯资本 →$60 升级 中性→购买
2020/05/15 - 古根海姆 升级 中性→购买
2020/05/14 1105.48% 卡纳科特·格纳奇 $36→$44 维护 买
2020/05/14 1269.86% 奥本海默 $44→$50 维护 跑赢大盘
2020/05/14 1050.68% HC Wainwright公司 $35→$42 重申 →购买
2020/05/14 776.71% SunTrust Robinson Humphrey $29→$32 评级下调 购买→Hold
04/13/2020 694.52% SunTrust Robinson Humphrey →$29 开始承保 →购买
02/24/2020 639.73% 贝伦伯格 →$27 开始承保 →保留
2019年12月18日 913.7% JMP证券 →$37 开始承保 →市场跑赢大盘
2019/11/04 886.3% 卡纳科特·格纳奇 →$36 开始承保 →购买
2019年08月09日 913.7% BTIG →$37 开始承保 →购买
2019年05月06日 612.33% 罗斯资本 →$26 开始承保 →中性
2019年05月31日 - 古根海姆 开始承保 →中性
2019年05月23日 639.73% Stifel →$27 开始承保 →保留
2019年05月03日 1132.88% 奥本海默 →$45 开始承保 →跑赢大盘
2019/03/29 1269.86% 派珀·桑德勒 →$50 开始承保 →超重
2019年03月15日 995.89% 雷蒙德·詹姆斯 →$40 开始承保 →跑赢大盘
2019/03/14 - 威廉·布莱尔 开始承保 →跑赢大盘
2018年11月05日 - 考恩公司 开始承保 →跑赢大盘
2018年11月05日 694.52% 摩根大通 →$29 开始承保 →中性
2018年11月05日 749.32% 杰富瑞 →$31 开始承保 →购买
2018年11月05日 1023.29% 高盛 →$41 开始承保 →购买

What is the target price for Allogene Therapeutics (ALLO)?

同种异体基因治疗(ALLO)的目标价格是多少？

The latest price target for Allogene Therapeutics (NASDAQ: ALLO) was reported by JP Morgan on September 25, 2023. The analyst firm set a price target for $9.00 expecting ALLO to rise to within 12 months (a possible 146.58% upside). 31 analyst firms have reported ratings in the last year.

摩根大通于2023年9月25日报道了异基因治疗公司(纳斯达克：ALLO)的最新目标价。这家分析公司将目标价定为9美元，预计Allo将在12个月内上涨至(可能上涨146.58%)。过去一年，31家分析公司公布了评级。

What is the most recent analyst rating for Allogene Therapeutics (ALLO)?

同种异体基因治疗公司(Allo)的最新分析师评级是多少？

The latest analyst rating for Allogene Therapeutics (NASDAQ: ALLO) was provided by JP Morgan, and Allogene Therapeutics maintained their overweight rating.

纳斯达克公司(Aligene Treateutics)的最新分析师评级是由摩根大通提供的，该公司维持其增持评级。

When is the next analyst rating going to be posted or updated for Allogene Therapeutics (ALLO)?

异基因治疗公司(Allo)的下一次分析师评级将于何时发布或更新？

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Allogene Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Allogene Therapeutics was filed on September 25, 2023 so you should expect the next rating to be made available sometime around September 25, 2024.

分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与异种基因治疗公司的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。异基因治疗公司的上一次评级是在2023年9月25日提交的，所以你应该预计下一次评级将在2024年9月25日左右的某个时候提供。

Is the Analyst Rating Allogene Therapeutics (ALLO) correct?

分析师对同种异体基因治疗公司(Allo)的评级正确吗？

While ratings are subjective and will change, the latest Allogene Therapeutics (ALLO) rating was a maintained with a price target of $11.00 to $9.00. The current price Allogene Therapeutics (ALLO) is trading at is $3.65, which is out of the analyst's predicted range.

虽然评级是主观的，并将发生变化，但最新的异基因治疗(Allo)评级保持不变，目标价在11.00美元至9.00美元之间。异基因治疗公司(Allo)目前的交易价格为3.65美元，超出了分析师的预测范围。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发